Masataka Tsuge Selected Research

daclatasvir

1/2020	Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
12/2018	Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.
4/2018	Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.
1/2018	Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
4/2017	Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.
4/2017	Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
3/2017	Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
1/2017	The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
1/2017	Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.
12/2016	Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masataka Tsuge Research Topics

Disease

59	Infections 02/2022 - 03/2005
47	Hepatocellular Carcinoma (Hepatoma) 06/2021 - 10/2005
38	Chronic Hepatitis C 01/2021 - 05/2009
21	Chronic Hepatitis B 01/2022 - 11/2006
19	Liver Cirrhosis (Hepatic Cirrhosis) 01/2021 - 09/2010
18	Neoplasms (Cancer) 06/2021 - 10/2005
16	Hepatitis B 01/2022 - 08/2004
15	Fibrosis (Cirrhosis) 11/2020 - 09/2010
12	Hepatitis C 09/2020 - 05/2009
8	Liver Diseases (Liver Disease) 03/2022 - 09/2010
6	Thrombosis (Thrombus) 04/2021 - 06/2015
6	Hepatic Encephalopathy 11/2020 - 07/2013
6	Disease Progression 04/2020 - 12/2007
5	Hepatitis 01/2021 - 02/2012
5	Neoplasm Metastasis (Metastasis) 01/2021 - 06/2015
5	Non-alcoholic Fatty Liver Disease 08/2020 - 03/2014
5	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 05/2017 - 07/2010
4	Type 2 Diabetes Mellitus (MODY) 01/2018 - 03/2014
3	Insulin Resistance 03/2022 - 12/2014
3	Carcinogenesis 01/2021 - 10/2005
3	Chronic Hepatitis (Chronic Active Hepatitis) 01/2020 - 03/2017
3	Acute Liver Failure (Fulminant Hepatic Failure) 12/2017 - 08/2014
3	Anemia 06/2017 - 06/2011
2	Glucose Intolerance 03/2022 - 02/2017
2	Hypoglycemia (Reactive Hypoglycemia) 03/2022 - 02/2017
2	Virus Diseases (Viral Diseases) 01/2022 - 03/2015
2	Liver Failure 02/2021 - 06/2008
2	Necrosis 01/2021 - 01/2018
2	Microsatellite Instability 10/2020 - 07/2020
2	Edema (Dropsy) 02/2020 - 08/2016
2	Sarcopenia 02/2020 - 03/2019
2	Brain Diseases (Brain Disorder) 08/2019 - 07/2014
2	Inflammation (Inflammations) 07/2019 - 09/2010

Drug/Important Bio-Agent (IBA)

48	InterferonsIBA 01/2022 - 05/2007
25	Ribavirin (Virazole)FDA LinkGeneric 01/2020 - 01/2010
23	Antiviral Agents (Antivirals)IBA 02/2022 - 09/2013
14	daclatasvirIBA 01/2020 - 01/2014
13	asunaprevirIBA 01/2020 - 06/2016
12	Sorafenib (BAY 43-9006)FDA Link 01/2021 - 06/2015
11	AntigensIBA 01/2022 - 02/2012
10	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2022 - 12/2015
10	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2006
10	RNA (Ribonucleic Acid)IBA 12/2021 - 06/2008
10	lenvatinibIBA 06/2021 - 01/2019
9	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 03/2005
6	Alanine Transaminase (SGPT)IBA 01/2021 - 06/2009
6	NucleosidesIBA 01/2019 - 05/2007
6	telaprevirIBA 06/2016 - 09/2011
5	Glucose (Dextrose)FDA LinkGeneric 03/2022 - 03/2014
5	CytokinesIBA 12/2021 - 09/2010
5	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 07/2012
5	SofosbuvirIBA 11/2020 - 04/2017
5	NucleotidesIBA 01/2019 - 10/2013
5	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 05/2017 - 07/2010
5	Lamivudine (Epivir)FDA Link 08/2010 - 11/2005
4	Hemoglobins (Hemoglobin)IBA 03/2022 - 06/2011
4	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2012
4	EnzymesIBA 02/2021 - 06/2008
4	regorafenibIBA 01/2021 - 09/2018
4	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 10/2015
4	Protease Inhibitors (Protease Inhibitor)IBA 04/2020 - 07/2010
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2018
4	Pharmaceutical PreparationsIBA 08/2019 - 11/2006
4	SimeprevirIBA 03/2017 - 06/2016
3	Small Interfering RNA (siRNA)IBA 01/2022 - 02/2006
3	Immunoglobulin G (IgG)IBA 01/2021 - 06/2008
3	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2020
3	Viral AntigensIBA 10/2020 - 02/2012
3	nasIBA 08/2020 - 02/2012
3	ChemokinesIBA 07/2019 - 01/2011
3	entecavir FDA Link 12/2018 - 12/2007
3	ledipasvirIBA 12/2018 - 04/2017
3	Hepatitis B e AntigensIBA 01/2018 - 10/2013
3	Complementary DNA (cDNA)IBA 05/2017 - 01/2011
2	Blood Glucose (Blood Sugar)IBA 03/2022 - 01/2018
2	LuciferasesIBA 01/2022 - 12/2021
2	Circulating Tumor DNAIBA 06/2021 - 09/2015
2	Immune Checkpoint InhibitorsIBA 02/2021 - 10/2020
2	glecaprevir and pibrentasvirIBA 01/2021 - 01/2020
2	Prothrombin (Factor II)IBA 01/2021 - 12/2017
2	HLA-DQB1 antigen (HLA DQB1)IBA 12/2020 - 01/2013
2	Histone MethyltransferasesIBA 11/2020 - 10/2005
2	Fetal Proteins (Fetoprotein)IBA 11/2020 - 01/2018
2	pembrolizumabIBA 10/2020 - 07/2020
2	Tenofovir (Viread)FDA Link 10/2020 - 01/2016
2	pibrentasvirIBA 04/2020 - 03/2019
2	glecaprevirIBA 04/2020 - 03/2019
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 03/2020 - 07/2016
2	ImmunosorbentsIBA 01/2020 - 06/2008
2	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2020 - 05/2016
2	BilirubinIBA 10/2019 - 12/2017
2	AlbuminsIBA 10/2019 - 07/2016
2	AmmoniaIBA 08/2019 - 01/2019

Therapy/Procedure

76	Therapeutics 01/2022 - 05/2009
13	Liver Transplantation 01/2021 - 12/2010
11	Drug Therapy (Chemotherapy) 04/2021 - 04/2015
4	Surgical Portasystemic Shunt (Portosystemic Shunt) 08/2019 - 07/2013
3	Radiotherapy 04/2021 - 01/2018
2	Glycemic Control 03/2022 - 03/2014
2	Hepatectomy 08/2019 - 09/2015